Case Reports
doi: 10.1056/NEJMoa051586.
Epub 2005 Jun 9.
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
Affiliations
- PMID: 15947080
- DOI: 10.1056/NEJMoa051586
Item in Clipboard
Case Reports
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
N Engl J Med.
.
Free article
Abstract
The prior diagnosis of fatal astrocytoma in a 60-year-old man with Crohn's disease treated with natalizumab, a monoclonal antibody against alpha4 integrins, was reclassified as JC virus-related progressive multifocal leukoencephalopathy (PML). Analysis of frozen serum samples showed that JC virus DNA had appeared in the serum three months after the initiation of open-label natalizumab monotherapy and two months before the appearance of symptomatic PML. There was staining of the brain lesion for polyomavirus. This case report, along with two others, suggests that anti-alpha4-integrin therapy can result in JC virus-induced PML.
Copyright 2005 Massachusetts Medical Society.
Comment in
-
Patients at risk.N Engl J Med. 2005 Jul 28;353(4):417. doi: 10.1056/NEJMe058123. Epub 2005 Jun 9. N Engl J Med. 2005. PMID: 15947081 No abstract available.
-
Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.N Engl J Med. 2005 Jul 28;353(4):414-6. doi: 10.1056/NEJMe058122. Epub 2005 Jun 9. N Engl J Med. 2005. PMID: 15947082 No abstract available.
Similar articles
-
JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?Gut. 2008 Oct;57(10):1393-7. doi: 10.1136/gut.2007.145698. Epub 2008 Apr 24. Gut. 2008. PMID: 18436577
-
Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.N Engl J Med. 2005 Jul 28;353(4):375-81. doi: 10.1056/NEJMoa051847. Epub 2005 Jun 9. N Engl J Med. 2005. PMID: 15947078
-
Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.N Engl J Med. 2005 Jul 28;353(4):369-74. doi: 10.1056/NEJMoa051782. Epub 2005 Jun 9. N Engl J Med. 2005. PMID: 15947079
-
Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.Expert Rev Gastroenterol Hepatol. 2007 Oct;1(1):29-39. doi: 10.1586/17474124.1.1.29. Expert Rev Gastroenterol Hepatol. 2007. PMID: 19072431 Review.
-
Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.Curr Opin Neurol. 2006 Aug;19(4):341-9. doi: 10.1097/01.wco.0000236612.66839.a2. Curr Opin Neurol. 2006. PMID: 16914971 Review.
Cited by
-
Advancements in Inflammatory Bowel Disease Management: From Traditional Treatments to Monoclonal Antibodies and Future Drug Delivery Systems.Pharmaceutics. 2024 Sep 7;16(9):1185. doi: 10.3390/pharmaceutics16091185. Pharmaceutics. 2024. PMID: 39339221 Free PMC article. Review.
-
Unveiling the Enigma: John Cunningham Virus-Associated Progressive Multifocal Leukoencephalopathy in an Immunocompetent Individual.Cureus. 2024 Jul 17;16(7):e64758. doi: 10.7759/cureus.64758. eCollection 2024 Jul. Cureus. 2024. PMID: 39156324 Free PMC article.
-
Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment.Medicine (Baltimore). 2024 Feb 23;103(8):e37297. doi: 10.1097/MD.0000000000037297. Medicine (Baltimore). 2024. PMID: 38394496 Free PMC article. Review.
-
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD012186. doi: 10.1002/14651858.CD012186.pub2. Cochrane Database Syst Rev. 2023. PMID: 38032059 Review.
-
Revisiting JC virus and progressive multifocal leukoencephalopathy.J Neurovirol. 2023 Oct;29(5):524-537. doi: 10.1007/s13365-023-01164-w. Epub 2023 Sep 2. J Neurovirol. 2023. PMID: 37659983 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
